Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014159166> ?p ?o ?g. }
- W3014159166 abstract "The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy). Dual therapy was noninferior for risk of thromboembolic events. Whether these results apply equally to patients at higher risk of ischemic events due to lesion complexity or clinical risk factors is unclear.The primary end point was time to first major or clinically relevant nonmajor bleeding event. The composite efficacy end point was death, thromboembolic event, or unplanned revascularization. Our prespecified subgroup analysis categorized patients by presence of procedural complexity and/or clinical complexity factors at baseline. A modified dual antiplatelet therapy score categorized patients according to degree of clinical risk.Of 2725 patients, 43.1% had clinical complexity factors alone, 9.9% procedural factors alone, 10.0% both, and 37.0% neither. Risk of the primary bleeding end point was lower in both dabigatran dual therapy groups than warfarin triple therapy groups, regardless of procedural and/or clinical lesion complexity (interaction P values: 0.90 and 0.37, respectively). Importantly, a similar risk of the efficacy end point was observed between dabigatran dual and warfarin triple therapy, regardless of the presence of clinical or procedural complexity factors (interaction P values: 0.67 and 0.54, dabigatran 110 and 150 mg dual therapy, respectively). Similar benefit was seen for each dose of dabigatran dual therapy for bleeding events regardless of dual antiplatelet therapy score (interaction P values: 0.53 and 0.54, respectively), with similar risk of thromboembolic events (interaction P values: 0.20 and 0.08, respectively).In patients with atrial fibrillation undergoing percutaneous coronary intervention, dabigatran 110 and 150 mg dual therapy reduced bleeding risk compared with warfarin triple therapy, with a similar risk of thromboembolic outcomes, irrespective of procedural and/or clinical complexity and modified dual antiplatelet therapy score. Registration: URL: https://clinicaltrials.gov/; Unique identifier: NCT02164864." @default.
- W3014159166 created "2020-04-10" @default.
- W3014159166 creator A5007123733 @default.
- W3014159166 creator A5007643898 @default.
- W3014159166 creator A5009430890 @default.
- W3014159166 creator A5025592036 @default.
- W3014159166 creator A5026004870 @default.
- W3014159166 creator A5026602252 @default.
- W3014159166 creator A5056522927 @default.
- W3014159166 creator A5063859581 @default.
- W3014159166 creator A5081743465 @default.
- W3014159166 creator A5081852908 @default.
- W3014159166 creator A5085128848 @default.
- W3014159166 creator A5088579117 @default.
- W3014159166 date "2020-04-01" @default.
- W3014159166 modified "2023-10-03" @default.
- W3014159166 title "Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention" @default.
- W3014159166 cites W1981131402 @default.
- W3014159166 cites W2015249021 @default.
- W3014159166 cites W2076602637 @default.
- W3014159166 cites W2078973349 @default.
- W3014159166 cites W2125173296 @default.
- W3014159166 cites W2159370853 @default.
- W3014159166 cites W2165349656 @default.
- W3014159166 cites W2324839838 @default.
- W3014159166 cites W2406884255 @default.
- W3014159166 cites W2508853990 @default.
- W3014159166 cites W2515533568 @default.
- W3014159166 cites W2550855468 @default.
- W3014159166 cites W2556417520 @default.
- W3014159166 cites W2749929702 @default.
- W3014159166 cites W2752033985 @default.
- W3014159166 cites W2766648702 @default.
- W3014159166 cites W2792857103 @default.
- W3014159166 cites W2802512131 @default.
- W3014159166 cites W2888082174 @default.
- W3014159166 cites W2892105291 @default.
- W3014159166 cites W2917582759 @default.
- W3014159166 cites W2921724943 @default.
- W3014159166 cites W2949986921 @default.
- W3014159166 cites W2955826609 @default.
- W3014159166 cites W3004050106 @default.
- W3014159166 cites W3025095208 @default.
- W3014159166 cites W3126662497 @default.
- W3014159166 cites W4205645630 @default.
- W3014159166 doi "https://doi.org/10.1161/circinterventions.119.008349" @default.
- W3014159166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32252548" @default.
- W3014159166 hasPublicationYear "2020" @default.
- W3014159166 type Work @default.
- W3014159166 sameAs 3014159166 @default.
- W3014159166 citedByCount "14" @default.
- W3014159166 countsByYear W30141591662020 @default.
- W3014159166 countsByYear W30141591662021 @default.
- W3014159166 countsByYear W30141591662022 @default.
- W3014159166 countsByYear W30141591662023 @default.
- W3014159166 crossrefType "journal-article" @default.
- W3014159166 hasAuthorship W3014159166A5007123733 @default.
- W3014159166 hasAuthorship W3014159166A5007643898 @default.
- W3014159166 hasAuthorship W3014159166A5009430890 @default.
- W3014159166 hasAuthorship W3014159166A5025592036 @default.
- W3014159166 hasAuthorship W3014159166A5026004870 @default.
- W3014159166 hasAuthorship W3014159166A5026602252 @default.
- W3014159166 hasAuthorship W3014159166A5056522927 @default.
- W3014159166 hasAuthorship W3014159166A5063859581 @default.
- W3014159166 hasAuthorship W3014159166A5081743465 @default.
- W3014159166 hasAuthorship W3014159166A5081852908 @default.
- W3014159166 hasAuthorship W3014159166A5085128848 @default.
- W3014159166 hasAuthorship W3014159166A5088579117 @default.
- W3014159166 hasBestOaLocation W30141591661 @default.
- W3014159166 hasConcept C126322002 @default.
- W3014159166 hasConcept C164705383 @default.
- W3014159166 hasConcept C2776301958 @default.
- W3014159166 hasConcept C2777849778 @default.
- W3014159166 hasConcept C2778810321 @default.
- W3014159166 hasConcept C2779161974 @default.
- W3014159166 hasConcept C2780400711 @default.
- W3014159166 hasConcept C2780890252 @default.
- W3014159166 hasConcept C45393284 @default.
- W3014159166 hasConcept C500558357 @default.
- W3014159166 hasConcept C71924100 @default.
- W3014159166 hasConceptScore W3014159166C126322002 @default.
- W3014159166 hasConceptScore W3014159166C164705383 @default.
- W3014159166 hasConceptScore W3014159166C2776301958 @default.
- W3014159166 hasConceptScore W3014159166C2777849778 @default.
- W3014159166 hasConceptScore W3014159166C2778810321 @default.
- W3014159166 hasConceptScore W3014159166C2779161974 @default.
- W3014159166 hasConceptScore W3014159166C2780400711 @default.
- W3014159166 hasConceptScore W3014159166C2780890252 @default.
- W3014159166 hasConceptScore W3014159166C45393284 @default.
- W3014159166 hasConceptScore W3014159166C500558357 @default.
- W3014159166 hasConceptScore W3014159166C71924100 @default.
- W3014159166 hasIssue "4" @default.
- W3014159166 hasLocation W30141591661 @default.
- W3014159166 hasLocation W30141591662 @default.
- W3014159166 hasLocation W30141591663 @default.
- W3014159166 hasLocation W30141591664 @default.
- W3014159166 hasLocation W30141591665 @default.
- W3014159166 hasOpenAccess W3014159166 @default.
- W3014159166 hasPrimaryLocation W30141591661 @default.
- W3014159166 hasRelatedWork W2344460484 @default.